Last reviewed · How we verify
Sufentanil + Lidocaïne
Sufentanil is a potent opioid analgesic that acts as a mu-opioid receptor agonist, while Lidocaïne is a local anesthetic that blocks sodium channels.
Sufentanil is a potent opioid analgesic that acts as a mu-opioid receptor agonist, while Lidocaïne is a local anesthetic that blocks sodium channels. Used for Pain management during surgery.
At a glance
| Generic name | Sufentanil + Lidocaïne |
|---|---|
| Also known as | Sufentanil + Xylocaïne® |
| Sponsor | University Hospital, Montpellier |
| Drug class | Opioid analgesic |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
Sufentanil's mechanism of action involves binding to the mu-opioid receptor, which activates G-protein coupled signaling pathways that ultimately lead to analgesia. Lidocaïne, on the other hand, works by blocking sodium channels in nerve cells, preventing the initiation and transmission of nerve impulses and thereby producing local anesthesia.
Approved indications
- Pain management during surgery
Common side effects
- Respiratory depression
- Nausea and vomiting
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |